Severe thrombocytopenia induced by a occlude for PDA: A medical device surveillance case report
DOI:
https://doi.org/10.35434/rcmhnaaa.2023.161.1719Keywords:
Patent ductus arteriosus, PDA occluder, thrombocytopenia, medical devices SurveillanceAbstract
Introduction: Patent ductus arteriosus (PDA) is a congenital heart condition of special interest. Interventional occlusion is the treatment of choice; however, a PDA occlude, used in this procedure, is a medical device that rarely could lead to adverse events such as hemorrhage, thrombocytopenia, etc. Case report: We present a case of a pediatric patient with severe thrombocytopenia after surgery. During her hospitalization, platelet levels remained lower and, finally, she was fully recovered without any hematological manifestation. The case was reported as a suspected adverse incident related to PDA occlude. Conclusion: After performing a cause-root analysis, we concluded that the size of the PDA occlude may be the main cause of thrombocytopenia. This case demonstrates that medical devices could lead to adverse events. Thus, it is important for clinicians to implement medical device surveillance, mainly for high-risk medical devices.
Downloads
Metrics
References
Dice JE, Bhatia J. Patent Ductus Arteriosus: An Overview. J Pediatr Pharmacol Ther JPPT. 2007;12(3):138-46. doi: 10.5863/1551-6776-12.3.138
Olórtegui A, Adrianzén M. Incidencia estimada de las cardiopatías congénitas en niños menores de 1 año en el Perú. An Fac Med. Junio de 2007;68(2):113-24. ISSN 1025 - 5583
Shangai Shape Memory Alloy. MemoPart TM PDA Occlutech Oclusor, Instrucciones de uso. Occlutech Oclusor PDA. Julio de 2019.
Gałeczka M, Szkutnik M, Białkowski J, Litwin L, Smerdziński S, Knop M, Głowacki J, Fiszer R. Transcatheter patent ductus arteriosus closure: what have we learned after over 25 years? A single center experience with 1036 patients. Kardiol Pol. 2021 Mar 25;79(3):287-293.. Epub 2021 Feb 16. PMID: 33599452. doi: 10.33963/KP.15812
Zhang P., Zhu X., Severe Thrombocytopenia Complicating Transcatheter Occlusion of a Patent Ductus Arteriosus. Journal of invasive cardiology. Abril de 2013, 25(5):E88-E92
Abbot, AmplatzerTM duct occluders for closure of patent ductus arteriosis (PDA), Health care professionals, 2015
Cheng Z., Li M., Lv T., Xiang P., Bai Y., Ji X., Liu Y., Pu X., Yi Q. Clinical analysis of severe thrombocytopenia after interventional closure of patent ductus arteriosus in children Journal of Third Military Medical University, 2017 , 39(14): 1486-1492.
Backes CH, Rivera BK, Bridge JA, Armstrong AK, Boe BA, Berman DP, Fick T, Holzer RJ, Hijazi ZM, Abadir S, Justino H, Bergersen L, Smith CV, Kirpalani H. Percutaneous Patent Ductus Arteriosus (PDA) Closure During Infancy: A Meta-analysis. Pediatrics. 1 de febrero de 2017;139(2):e20162927. doi: 10.1542/peds.2016-2927
Li P, Chen F, Zhao X, Zheng X, Wu H, Chen S, Qin Y. Occurrence and clinical significance of in-hospital acquired thrombocytopenia in patients undergoing transcatheter device closure for congenital heart defect. Thrombosis Research. diciembre de 2012;130(6):882-8. doi: 10.1016/j.thromres.2012.09.001
Li A, Yin D, Huang X, Zhang L, Lv T, Yi Q, et al. Clinical Analysis of Thrombocytopenia following Transcatheter Occlusion of a Patent Ductus Arteriosus. Cardiology. 2021;146(2):253-7. doi: 10.1159/000512512
Liu L, Yue P, Zheng X, Liao H, Li J, Hua Y, et al. Thrombocytopenia associated with transcatheter closure of giant patent ductus arteriosus. Cardiology in the Young. diciembre de 2020;30(12):1896-901. doi: 10.1017/s1047951120003169
Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 15 de noviembre de 2012;120(20):4160-7. doi: 10.1182/blood-2012-07-443051
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Víctor E. Lechuga-Noa, L. Yesenia Rodríguez-Tanta, David G. Gálvez Caballero
This work is licensed under a Creative Commons Attribution 4.0 International License.